Nanobiotix S.A.
News
(4)April 2026
Nanobiotix platform improves cancer drug delivery and bioavailability in mouse models
# 📝 What This Document Is 📰 This document is a Form 6-K press release (Exhibit 99.1) announcing that Nanobiotix presented new, highly technical preclinical data at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). Essentially, the company is providing an early look at
Nanobiotix S.A. — 6-K Filing
# 🧾 What This Document Is This is a standard regulatory filing from **Nanobiotix (NBTX)**. It’s not an earnings report or a press release about a big discovery—it’s a required, routine update to inform the market about the company's **share structure and voting power** as of March 31, 2026. 👉 **
March 2026
Nanobiotix S.A. — 6-K Filing
# 🧾 What This Document Is This is a **6-K filing** from Nanobiotix, which is a current report foreign companies file with the SEC to share major news. It contains a press release that serves as a comprehensive business update and a report of their full financial results for 2025. Think of it as the
Nanobiotix S.A. — 6-K Filing
# 🧾 What This Document Is This is a **6-K report**, which is a form foreign companies like Nanobiotix (based in France) use to tell the U.S. market about important events. This one is essentially a press release sharing the first clinical trial results for one of their key drugs, presented at a ma
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.